Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2017: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
Outline of Final Research Achievements |
The aim of this study was identification of antiviral compounds that targeted host agents interacting proteins of hepatitis B and C viruses (HBV and HCV) based on proteomics information. FKBP6 and HM13 were identified as essential host proteins for HCV replication and the viral particle production and its pathogenicity. DM-CHX and cinnamic acid derivatives, which target them, prevented HCV replication and production. Furthermore, pTEFb inhibitor could suppress HBV replication and production. These results will contribute to development of novel antiviral agents targeting production and pathogenicity of HBV and HCV
|